The St. Jude Toronto stentless bioprosthesis: Up to 20 years follow-up in younger patients
Background:A retrospective long-term evaluation of the St. Jude Toronto stentless bioprosthesis in patients aged 60 years or younger.
Methods:From 1994 to 1997, 50 patients underwent aortic valve replacement with the prosthesis. Patients mean age at surgery was 54.5±6.3 years. Follow-up data were acquired by patient file research and telephone interviews. Morbidity and mortality were evaluated with time-to-event analyses using the Kaplan-Meier-method. The log-rank test was used to determine influencing factors for long-term survival and reoperation.
Results:Mean follow-up was 13.5±6.3 years with a total follow-up of 661.8 patient-years and a maximum of 20.0 years. Follow-up was 97.8% complete. Associated procedures were performed in 12 patients (24%), including coronary artery bypass grafting, mitral valve replacement and replacement of the ascending aorta. Freedom from reoperation at 10 and 15 years was 76.0±6.7% and 44.1±8.9%, respectively. Reoperations (n=26) started 4.4 years after implantation and were necessary due to: valve degeneration with regurgitation in 79.2% and stenosis in 12.5%, endocarditis in 4.2% and sinus valsalva aneurysm in 4.2% of the cases. The log-rank test revealed that only body-mass-index>25 lowered freedom-from-reoperation, while renal dysfunction, diabetes mellitus and arterial hypertension were not. Overall long-term survival at 10 and 20 years was 82.3±5.7% and 49.9±8.9%, respectively.
Conclusion:In younger patients the Toronto-bioprosthesis provided reliable long-term survival despite limited durability.
Bonow RO, Carabello B, de Leon AC Jr, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998;98(18):1949-1984.
Chiang YP, Chikwe J, Moskowitz AJ, Itagaki S, Adams DH, Egorova NN. Survival and Long-term Outcomes Following Bioprosthetic vs Mechanical Aortic Valve Replacement in Patients Aged 50 to 69 Years. JAMA 2014;312(13):1323. doi:10.1001/jama.2014.12679.
Christ T, Grubitzsch H, Claus B, Heinze G, Dushe S, Konertz W. Hemodynamic behavior of stentless aortic valves in long term follow-up. J. Cardiothorac. Surg. 2014;9(1):197. doi:10.1186/s13019-014-0197-2.
Christ T, Grubitzsch H, Claus B, Konertz W. Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age. J. Thorac. Cardiovasc. Surg. 2014;147(1):264-269. doi:10.1016/j.jtcvs.2012.10.032.
Christ T, Grubitzsch H, Claus B, Konertz W. Stentless aortic valve replacement in the young patient: long-term results. J. Cardiothorac. Surg. 2013;8(1):68. doi:10.1186/1749-8090-8-68.
David TE, Feindel CM, Bos J, Ivanov J, Armstrong S. Aortic valve replacement with Toronto SPV bioprosthesis: Optimal patient survival but suboptimal valve durability. J. Thorac. Cardiovasc. Surg. 2008;135(1):19–24.
Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J. Am. Coll. Cardiol. 2000;36(4):1152.
Kobayashi J. Stentless aortic valve replacement: an update. Vasc. Health Risk Manag. 2011;7:345-351. doi:10.2147/VHRM.S11253.
Konertz W, Herrmann M, Knauth M, Stabenow I, David T. Preliminary experience with the Toronto SPV stentless porcine bioprosthesis for aortic valve replacement. Thorac. Cardiovasc. Surg. 1994;42(1):36-39. doi:10.1055/s-2007-1016452.
Kunadian B, Vijayalakshmi K, Thornley AR, et al. Meta-Analysis of Valve Hemodynamics and Left Ventricular Mass Regression for Stentless Versus Stented Aortic Valves. Ann. Thorac. Surg. 2007;84(1):73-78. doi:10.1016/j.athoracsur.2007.02.057.
Lehmann S, Walther T, Kempfert J, et al. Stentless Versus Conventional Xenograft Aortic Valve Replacement: Midterm Results of a Prospectively Randomized Trial. Ann. Thorac. Surg. 2007;84(2):467-472. doi:10.1016/j.athoracsur.2007.02.017.
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. J. Am. Coll. Cardiol. 2014;63(22):e57-e185. doi:10.1016/j.jacc.2014.02.536.
Oxenham H, Bloomfield P, Wheatley DJ, et al. Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. Heart Br. Card. Soc. 2003;89(7):715-721.
Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J. Am. Coll. Cardiol. 2010;55(22):2413-2426. doi:10.1016/j.jacc.2009.10.085.
Ruel M, Chan V, BÃ©dard P, et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults <60 years of age. Circulation 2007;116(11 Suppl):I294-300. doi:10.1161/CIRCULATIONAHA.106.681429.
Sidiropoulos A, Hotz H, Tschesnow J, Konertz W. Stentless porcine bioprostheses for all types of aortic root pathology. Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 1997;11(5):917-921.
Statistisches Bundesamt Wiesbaden, ed. BevÃ¶lkerung und ErwerbstÃ¤tigkeit, Fachserie 1, Reihe 1, Gebiet und BevÃ¶lkerung 1993: Ed. Statistisches Bundesamt Wiesbaden, Metzler-Poeschel Verlag, Stuttgart 1995, 178-179.
Une D, Ruel M, David TE. Twenty-year durability of the aortic Hancock II bioprosthesis in young patients: is it durable enough? Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 2014;46(5):825-830. doi:10.1093/ejcts/ezu014.
Valfre C, Ius P, Minniti G, et al. The fate of Hancock II porcine valve recipients 25 years after implant. Eur. J. Cardiothorac. Surg. 2010;38(2):141.
Walther T, Falk V, Langebartels G, et al. Prospectively randomized evaluation of stentless versus conventional biological aortic valves: impact on early regression of left ventricular hypertrophy. Circulation 1999;100(19 Suppl):II6-10.
Welke KF, Wu Y, Grunkemeier GL, Ahmad A, Starr A. Long-term Results after Carpentier-Edwards Pericardial Aortic Valve Implantation, with Attention to the Impact of Age. Heart Surg. Forum 2011;14(3):E160-165. doi:10.1532/HSF98.20101140.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).